News
Dynavax Technologies (DVAX) Q1 2024 Earnings Call Transcript
Image source: The Motley Fool.
Dynavax Technologies (NASDAQ: DVAX)Q1 2024 Earnings CallMay 08, 2024, 4:30 p.m. ET
Operator
Source Fool.com
MannKind (MNKD) Q1 2024 Earnings Call Transcript
Image source: The Motley Fool.
MannKind (NASDAQ: MNKD)Q1 2024 Earnings CallMay 08, 2024, 5:00 p.m. ET
Operator
Source Fool.com
Karyopharm Therapeutics (KPTI) Q1 2024 Earnings Call Transcript
Image source: The Motley Fool.
Karyopharm Therapeutics (NASDAQ: KPTI)Q1 2024 Earnings CallMay 08, 2024, 8:00 a.m. ET
Operator
Source Fool.com
Agenus (AGEN) Q1 2024 Earnings Call Transcript
Image source: The Motley Fool.
Agenus (NASDAQ: AGEN)Q1 2024 Earnings CallMay 07, 2024, 8:30 a.m. ET
Operator
Source Fool.com
EQS-News: Biotest AG: Annual General Meeting approves dividend distribution
EQS-News: Biotest increased sales by 83.6% to Euro 215.2 million in first quarter 2024
Axsome Therapeutics (AXSM) Q1 2024 Earnings Call Transcript
Image source: The Motley Fool.
Axsome Therapeutics (NASDAQ: AXSM)Q1 2024 Earnings CallMay 06, 2024, 8:00 a.m. ET
Operator
Source Fool.com
Geron (GERN) Q1 2024 Earnings Call Transcript
Image source: The Motley Fool.
Geron (NASDAQ: GERN)Q1 2024 Earnings CallMay 02, 2024, 8:00 a.m. ET
Operator
Source Fool.com
3 Beaten-Down Stocks I Wouldn't Touch With a 10-Foot Pole
The market isn't rational always and everywhere. Sometimes, shares of excellent companies with bright futures almost inexplicably fail to keep pace with broader equities. When that happens, it's
Is Viking Therapeutics Incredibly Undervalued?
Viking Therapeutics (NASDAQ: VKTX) has emerged as a beacon of hope in an otherwise lackluster year for healthcare stocks. The buzz around its mid-stage weight loss candidate, VK2735, has propelled
Can This High-Flying Stock 10x in 10 Years?
Viking Therapeutics (NASDAQ: VKTX) has been flying on all cylinders since the beginning of the year. The company's shares are up 246% due to excellent clinical progress. It's not rare for smaller
Up 40%: Is This Red-Hot Growth Stock Still a Buy?
Last Friday, Agenus (NASDAQ: AGEN), an immuno-oncology player, saw its shares soar by a staggering 40.8%. This remarkable rally occurred seemingly without a clear catalyst. The company is set to
EQS-News: Biotest AG opens 12th plasma collection centre in Germany
Billionaires Are Buying These 2 Ultra-High Yield Dividend Stocks Hand Over Fist. Are They Smart Buys for Your Portfolio?
Investors looking for stocks that can produce heaps of passive income want to look at recent activity from some of the world's most successful investors. Billionaire hedge fund manager Ken Griffin
2 Stocks Down 30% to Buy Right Now
The bull market is roaring higher, and many growth stocks have led the gains -- but this doesn't mean your opportunity to buy growth stocks for a good price is over. Plenty of players with great
Better Buy: Bluebird Bio Vs. Novavax
If there is one thing Bluebird Bio (NASDAQ: BLUE) and Novavax (NASDAQ: NVAX) have in common, other than their belonging to the biotech industry, it is that both have seen their shares drop
3 Magnificent Stocks That Could Double or More by 2030
Does a 100% return in less than seven years sound pretty good? Most investors would probably say so. But which stocks are good candidates to achieve such a gain?
Three Motley Fool contributors think
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week
Many stocks were wobbly over the past few trading days, but we can't say that about biotech AnaptysBio (NASDAQ: ANAB). The company's shares closed the week almost 8% higher in price, according to
Down 60% From Its 52-Week High, Is Novavax Stock a Buy?
In just the past 12 months, Novavax (NASDAQ: NVAX) stock has plummeted 48% in value. The once-promising COVID vaccine maker has struggled mightily; it was late to getting a vaccine approved and to
Cathie Wood Goes Bargain Hunting. 2 Stocks She Bought This Week.
Cathie Wood is known for her investments in disruptive technologies that are changing or have the potential to change the way things are done. She's built a solid reputation as a stock picker
2 Under-the-Radar Growth Stocks to Consider
Exciting growth stocks are highly coveted, but some fly under the radar for various reasons. And this gives astute investors the opportunity to pounce before their shares rise significantly.
Mid-cap
Better Buy: CRISPR Therapeutics Vs. Viking Therapeutics
CRISPR Therapeutics (NASDAQ: CRSP) and Viking Therapeutics (NASDAQ: VKTX) are among the hottest mid-cap biotechs on the market. Both have delivered incredible progress in recent months, be it on the
Viking Therapeutics Is Great. Here's Why You Shouldn't Buy It.
Viking Therapeutics (NASDAQ: VKTX) has shown its strengths from a potential product perspective and an investment perspective in recent times. The company reported excellent data from clinical
Down 75%. Is Agenus Stock a Buy on the Dip?
The past nine months have been rough ones to be an Agenus (NASDAQ: AGEN) shareholder. The stock has collapsed by about 75% from the peak it set last June.
Investment bank analysts on Wall Street who
Is it Too Late to Buy Viking Therapeutics Stock?
One of the hottest areas of the pharmaceutical industry right now is the weight loss treatment space. Novo Nordisk and Eli Lilly have been the primary innovators. Their groundbreaking glucagon-like